| DIRECT COMPETITOR COMPARISON | |
| CGEN | AMGN | BAYRY.PK | Pvt1 | Industry | | Market Cap: | 79.09M | 58.20B | N/A | N/A | 102.37M | | Employees: | 57 | 16,700 | N/A | 701 | 65 | | Qtrly Rev Growth (yoy): | N/A | -1.60% | N/A | N/A | 19.70% | | Revenue (ttm): | 236.00K | 14.58B | N/A | 8.20M1 | 14.01M | | Gross Margin (ttm): | 100.00% | 84.99% | N/A | N/A | 65.68% | | EBITDA (ttm): | -9.02M | 6.71B | N/A | N/A | -12.30M | | Oper Margins (ttm): | -3,973.31% | 38.71% | N/A | N/A | -137.11% | | Net Income (ttm): | -5.58M | 4.74B | N/A | N/A | N/A | | EPS (ttm): | -0.195 | 4.585 | N/A | N/A | -0.32 | | P/E (ttm): | N/A | 12.54 | N/A | N/A | 16.19 | | PEG (5 yr expected): | N/A | 1.32 | 2.71 | N/A | 1.32 | | P/S (ttm): | 337.54 | 3.96 | N/A | N/A | 9.50 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.50 | 0.74% | 58.20B | 12.54 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.74 | -0.21% | 13.81B | 15.98 | | Genzyme Corp. | GENZ | 51.29 | 0.35% | 13.61B | 29.24 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.54 | 0.30% | 41.88B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 51.04 | 0.55% | 9.10B | 1041.63 | | Teva Pharmaceutical Industries Limited | TEVA | 53.94 | 1.05% | 47.52B | 49.35 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.68 | 0.35% | 4.00B | 19.42 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.77 | -1.01% | 2.92B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.51 | 1.54% | 5.66B | 113.56 | | Pfizer Inc. | PFE | 18.74 | -0.58% | 151.22B | 15.56 | | Johnson & Johnson | JNJ | 63.88 | 0.58% | 176.25B | 13.95 | | GlaxoSmithKline plc | GSK | 42.38 | -0.07% | 107.43B | 13.50 | | Sanofi-Aventis | SNY | 39.75 | 1.09% | 103.79B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.77 | -0.69% | 126.66B | 16.70 | | RHHBY.PK | 41.43 | 0.07% | N/A | N/A | | AstraZeneca plc | AZN | 45.93 | 0.42% | 66.60B | 9.22 | | Abbott Laboratories | ABT | 54.44 | -0.07% | 84.20B | 14.75 | | Bristol-Myers Squibb Co. | BMY | 24.77 | 0.49% | 49.07B | 12.81 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | AMGN | | Tired of Waiting, Teva Advances
Wed 3:31pm -
at Motley Fool | | • | AMGN | | Buy This Investment If You Want to Lose Money
Wed 3:29pm -
at Motley Fool | | • | AMGN | | [$$] Teva Carries Israel and Biotech ETFs
Wed 9:46am -
at RealMoney by TheStreet.com | | • | AMGN | | Another View: Innovation Can Unlock Job Growth
Wed 1:47am -
at The New York Times | | • | AMGN | | UPDATE - Teva seeks FDA nod for biosimilar of Amgen drug
Tue 11:41am -
at Reuters | | • | BAYRY.PK | | Biotech Stocks: Europe drug stocks rally; Cephalon slides
Mon, Nov 23 -
at MarketWatch | | • | BAYRY.PK | | UK health unit rejects Bayer drug as too expensive
Thu, Nov 19 -
at MarketWatch | | • | BAYRY.PK | | Oculus Wins China Approval for Animal Wound Product
Tue, Nov 17 -
at Seeking Alpha | | • | BAYRY.PK | | Trading Outlook for BioElectronics Corporation Issued by StockPreacher.com
Thu, Nov 12 -
GlobeNewswire | | • | BAYRY.PK | | CEO Interview: Aeolus Pharmaceuticals, Inc. - John L. McManus
Mon, Nov 2 -
Wall Street Transcript | | • | BAYRY.PK | | The World's Top Chemical Companies
Mon, Nov 2 -
at Seeking Alpha | | • | BAYRY.PK | | Bayer Disappoints
Wed, Oct 28 -
Zacks.com | | • | BAYRY.PK | | Bayer Earnings Call scheduled for 10:00 am ET today
Tue, Oct 27 -
CCBN | | | All Headlines for these symbols... |
|
|
|
0.18% Nasdaq 
0.42%
Competitors
